Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

6.5K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Apoptosis01:30

Apoptosis

11.6K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
11.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026
Same author

A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition.

Journal of the American Chemical Society·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Retraction: Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.

The Journal of experimental medicine·2026
Same author

Peripheral Nerve Infiltration by CAR T-cells in a Case of Mononeuritis Multiplex after Ciltacabtagene Autoleucel.

Blood cell therapy·2026
Same author

Causal and directional elements of global brain dynamics.

bioRxiv : the preprint server for biology·2026

相关实验视频

Updated: Jul 21, 2025

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.4K

重新连接癌症驱动器以激活细胞亡

Sai Gourisankar1,2, Andrey Krokhotin1, Wenzhi Ji3

  • 1Department of Pathology, Stanford University, Stanford, CA, USA.

Nature
|July 26, 2023
PubMed
概括
此摘要是机器生成的。

科学家开发了新的转录/表观遗传化学诱导剂 (TCIPs),可激活癌细胞死亡途径. TCIP1有效向扩散的大B细胞淋巴瘤,包括耐药类型,提供一种新的治疗策略.

更多相关视频

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.6K
Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal
11:21

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal

Published on: January 26, 2019

10.0K

相关实验视频

Last Updated: Jul 21, 2025

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.4K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.6K
Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal
11:21

Flow Cytometric Detection of Newly-formed Breast Cancer Stem Cell-like Cells After Apoptosis Reversal

Published on: January 26, 2019

10.0K

科学领域:

  • 癌症学
  • 分子生物学
  • 化学生物学

背景情况:

  • 癌细胞利用驱动突变进行增殖和生存.
  • 细胞死亡途径通常会消除细胞,以使生物体受益.
  • 现有的癌症驱动因子可能会被重新连接以诱导细胞死亡.

研究的目的:

  • 引入一种新的分子类型,即转录性/表观遗传化学接近诱导剂 (TCIP).
  • 为了证明TCIP能够将癌症驱动因素引入细胞死亡基因促进剂.
  • 研究TCIPs在扩散性大B细胞淋巴瘤 (DLBCL) 的疗效.

主要方法:

  • 通过将向B细胞淋巴瘤6 (BCL6) 的小分子与BRD4等转录激活剂连接而设计的TCIP.
  • 使用强效分子TCIP1将BRD4引入BCL6结合部位.
  • 评估TCIP1对DLBCL细胞系的基因表达及其杀死功效.

主要成果:

  • TCIP1 增强了 BRD4 对目标基因促进者的结合,从而促进了亲细胞灭绝的基因表达.
  • 显示TCIP1具有强大的DLBCL细胞系杀伤能力,包括耐化疗和TP53突变细胞系 (EC50 1-10 nM).
  • TCIP1表现出细胞和组织特异性,突出结合转录特异性.

结论:

  • 在癌症中激活内源性细胞死亡途径的新方法是TCIP.
  • 对于DLBCL和其他恶性瘤,TCIP1具有显著的治疗潜力.
  • 该概念可以扩展到再生医学和发育障碍.